Differential intracellular processing of the anthracycline drug ME2303 in doxorubicin‐sensitive (A2780) and ‐resistant (A2780AD) human ovarian cancer cells as studied with confocal laser scanning microscopy and image analysis
暂无分享,去创建一个
[1] J. Baak,et al. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells. , 1993, British Journal of Cancer.
[2] Hamid Morjani,et al. Confocal fluorescence microscopy of living cells , 1993, Other Conferences.
[3] P. Workman,et al. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. , 1993, British Journal of Cancer.
[4] P. Workman,et al. Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance. , 1992, Anti-cancer drug design.
[5] K. Kiura,et al. Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines. , 1992, Acta medica Okayama.
[6] D. Marquardt,et al. Drug transport mechanisms in HL60 cells isolated for resistance to adriamycin: evidence for nuclear drug accumulation and redistribution in resistant cells. , 1992, Cancer research.
[7] J. Baak,et al. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. , 1991, British Journal of Cancer.
[8] A. Hoshi,et al. Antitumor Activity and Metabolism of a New Anthracycline‐containing Fluorine (ME2303) in Lewis Lung Carcinoma‐bearing Mice , 1991, Japanese journal of cancer research : Gann.
[9] J. Gervasoni,et al. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. , 1991, Cancer research.
[10] S. Mirski,et al. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. , 1991, Cancer research.
[11] M. Dietel,et al. Morphologic alterations in drug sensitive vs. drug resistant cells due to cytostatic application. , 1990, Cancer treatment reviews.
[12] H. Tapiero,et al. Can cytotoxic activity of anthracyclines be related to DNA damage? , 1990, Anti-cancer drug design.
[13] T. Tsuruo,et al. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines. , 1989, Cancer research.
[14] S. Kaye,et al. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. , 1989, Cancer research.
[15] K. Bhalla,et al. Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells. , 1989, Cancer research.
[16] F. Arcamone. Clinically useful doxorubicin analogues. , 1987, Cancer treatment reviews.
[17] I. Pastan,et al. Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. , 1986, Cancer research.
[18] E. Modest,et al. Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate. , 1976, Cancer research.
[19] N. Bachur,et al. Cytofluorescence localization of adriamycin and daunorubicin. , 1974, Cancer Research.
[20] Marc Buyse,et al. Cyclophosphamide Plus Cisplatin Versus Cyclophosphomide, Doxorubicin, and Cisplatin Chemotherapy of Ovarian-carcinoma - a Metaanalysis , 1991 .